Recursion Pharmaceuticals assumed with an Equal Weight at Morgan Stanley

Morgan Stanley assumed coverage of Recursion Pharmaceuticals (RXRX) with an Equal Weight rating and $5 price target Recursion has faced volatility due to a combination of macroeconomic factors, underperformance on initial clinical results and uncertainty on valuation and revenue drivers, the analyst tells investors in a research note. The recent pipeline prioritization and stage of clinical development for the proprietary pipeline leaves several open questions on valuation, the analyst tells investors in a research note.